You're here: Home » Agenda

Agenda

Paediatrics/Juvenile Tox 15/03/2012 - 13:30

posted by Brigitte

Fees : 150€ for the Members and 350€ for the non Members.

FINAL PROGRAMME

Thursday 15 March 2012 - De Montil, Affigem

Challenges and opportunities in Paediatric development.

The conference will clarify us on two main topics related to paediatric development
The first part of the afternoon session will focus on the importance of the Non-Clinical part in a paediatric development. Both the viewpoint from an assessor at the FAMHP, and an insight on how the industry copes with some specific requirements will be presented.

The second part starts with a lesson for the future by analysing the past. Five years after the implementation of the Paediatric regulation, the time has come to make an intermediate analysis. We will hear first-hand about the extensive experience of the PDCO (EMA) and have an actualised viewpoint on how the Paediatric Committee plans to continue their effort in the future. The last presentation covers various issues encountered by companies when introducing a PIP or claiming the SPC extension and proposes some possible practical ways to resolve them.

13.30 – 14.15 Non Clinical support to paediatric drug development.
Jacqueline Carleer, Safety Assessor, Research and Development, Federal Agency for Medicines and Health Products (FAMHP), Belgium, Alternate member of the Paediatric Committee (PDCO)

14.15 – 15.00 An industry approach on Juvenile toxicity testing.
Graham Bailey, ETS President, Senior Research Fellow (Reprotox) Toxicology and Pathology Drug Safety Sciences Janssen Pharmaceutica N.V.

15.00 – 15.30 Coffee

15.30 – 16.00 PDCO, where are we heading to?
Daniel Brasseur, Chair Paediatric Committee (PDCO), EMA London - FAMHP and Children's Hospital Queen Fabiola, Brussels, Belgium

16.00 – 16.45 Legal constraints and proposals to address them
Geneviève Michaux (Counsel), Covington & Burling LLP, Belgium

16.45 – 17.15 Panel discussion

A “must attend” seminar for professionals working in national, EU and International Regulatory Affairs and colleagues from Development, Clinical Research, Project Management, Legal & Patent Departments



 

Introduction to Regulatory Affairs 03/05/2012 - 09:00

posted by Brigitte

2 days Introduction to Regulatory Affairs

Date : 3 & 4 May 2012

Location : Federal Agency for Medicines and Healthcare Products

Speakers : FAMHP + usual external speakers

Fees : 900€ for BRAS Members and 1.100€ for non Members

Maximum 30 seats

Programme to follow.



 

BRAS Symposium 2012 18/10/2012 - 09:00

posted by Brigitte

National Symposium 2012

Date : Thursday 18 October 2012

Location : Sheraton Rogier

Speakers : FAMHP

Fees : 575€ for BRAS Members and 765€ for non BRAS Members

Programme to follow.